Jaime Modiano
Fundador en ApopLogic Pharmaceuticals, Inc. .
Cargos activos de Jaime Modiano
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Fundador | 01/08/2006 | - |
Historial de carrera de Jaime Modiano
Antiguos cargos conocidos de Jaime Modiano.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| University of Colorado Health Sciences Center | Corporate Officer/Principal | 01/01/2007 | 01/01/2007 |
| Texas A&M University | Corporate Officer/Principal | 01/01/1999 | 01/01/1999 |
| AMC Cancer Research Center | Corporate Officer/Principal | - | - |
Formación de Jaime Modiano.
| El Colegio de México AC | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
| México | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Consumer Services | 5 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
| AMC Cancer Research Center |
- Bolsa de valores
- Insiders
- Jaime Modiano
- Experiencia
